27th Jan 2025 10:15
(Alliance News) - RTW Biotech Opportunities Ltd on Monday said portfolio company Kailera Therapeutics has received positive results from a recent weight loss treatment trial.
Kailera Therapeutics is a Massachusetts-based obesity-focused therapy company, developing a broad, advanced and differentiated portfolio of clinical-stage injectable and oral therapies for chronic weight management.
The investment fund managed by RTW Investments LP that specialises in the life sciences sector said Kailera announced "positive topline data" from its phase 2 clinical trial of HRS9531, a treatment for people who are overweight or living with obesity.
The trial showed that an injection of the 8 milligram dose once a week demonstrated a statistically significant result of 21.1% mean weight loss at week 26, which was also a 22.8% mean change from the baseline. The treatment showed no plateau in weight loss.
Roderick Wong, managing partner & chief information officer at RTW Investments, said: "With 22.8% weight loss at 36 weeks, HRS9531 looks like a potentially best-in-class treatment for obesity and related conditions, beating the 21% shown by Eli Lilly & Co's retatrutide.
"These data increase our confidence that Kailera is one of the leading players in next-generation obesity management. Obesity is a major risk factor for a number of chronic diseases like diabetes, hypertension and liver disease, as well as cardiovascular disease such as heart disease and stroke, which are the leading causes of death worldwide and, as such, the treatment of it is a core focus for us."
Shares in RTW Biotech Opportunities were up 1.0% at USD1.33 each in London on Monday morning.
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.